Strengthening Families & Communities LLC Has $2.07 Million Stock Position in Boston Scientific Corporation $BSX

Strengthening Families & Communities LLC boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 2,478.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 21,402 shares of the medical equipment provider’s stock after buying an additional 20,572 shares during the quarter. Strengthening Families & Communities LLC’s holdings in Boston Scientific were worth $2,068,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the stock. Steph & Co. acquired a new position in shares of Boston Scientific during the third quarter valued at about $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific in the 3rd quarter valued at approximately $25,000. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. United Community Bank grew its holdings in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares in the last quarter. Finally, Kilter Group LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $30,000. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. The SEC filing for this sale provides additional information. 0.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. UBS Group reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. National Bankshares set a $115.00 target price on shares of Boston Scientific in a research report on Monday. BTIG Research reissued a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research note on Friday, November 21st. Evercore ISI set a $112.00 price target on shares of Boston Scientific in a research note on Monday, January 5th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $112.00 price objective on shares of Boston Scientific in a research note on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $123.89.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $91.83 on Tuesday. The stock has a market capitalization of $136.13 billion, a price-to-earnings ratio of 49.11, a P/E/G ratio of 1.66 and a beta of 0.67. The firm’s 50-day moving average price is $95.08 and its two-hundred day moving average price is $99.38. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.